| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/05/2001 | US6242435 Compositions and methods of treating abnormal cell proliferation |
| 06/05/2001 | US6242434 Treatment and prophylaxis of hyperparathyroidism and hyperproliferative diseases, and in the modulation of the immune and inflammatory responses as well as the treatment of bone depletive disorders. |
| 06/05/2001 | US6242424 Moenomycin and its derivatives for the production of pharmaceuticals, and pharmaceuticals containing moenomycin or its derivatives |
| 06/05/2001 | US6242249 Nucleotide sequences of trigger factor chaperones from staphylococcus; diagnosis; probes; primers; vaccines; bactericides; bacteriostats; antibodies; drug screening |
| 06/05/2001 | US6242205 Method of detecting drug-receptor and protein-protein interactions |
| 06/05/2001 | US6242203 Tumor-specific P450 protein |
| 06/05/2001 | US6242183 Interaction trap systems for detecting protein interactions |
| 06/05/2001 | US6242179 Nucleotide sequences coding eukaryotic hydrolase; for the diagnosis, prevention, and treatment of immune defects and cancers; anticarcinogenic agents |
| 06/05/2001 | US6241993 Therapeutic/cosmetic compositions comprising bradykinin antagonists for treating sensitive human skin |
| 06/05/2001 | US6241529 Affixing dosage unit comprised of a compressed tablet of a bioerodible polymeric carrier and androgenic agent, progestin, and estrogen to buccal mucosa; useful for female hormone replacement therapy, contraception, and sexual dysfunction |
| 06/05/2001 | CA2051621C Oil-in-water type emulsified composition comprising non-steroidal antiphlogistic and analgesic drug |
| 06/04/2001 | WO2001042474A2 Interferon-like molecules and uses thereof |
| 06/04/2001 | CA2395408A1 Interferon-like molecules and uses thereof |
| 05/31/2001 | WO2001038878A2 Pin1 as a marker for abnormal cell growth |
| 05/31/2001 | WO2001038567A2 Genetic indicators of tobacco consumption |
| 05/31/2001 | WO2001038564A2 Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy |
| 05/31/2001 | WO2001038532A2 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 05/31/2001 | WO2001038393A1 Polypeptides derived from vitamin d nuclear receptor, and their uses in particular for screening vitamin d analogues |
| 05/31/2001 | WO2001038392A1 Novel transcription factor and dna thereof |
| 05/31/2001 | WO2001038352A2 Methods of inhibiting metastasis |
| 05/31/2001 | WO2001038332A1 Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors |
| 05/31/2001 | WO2001038325A1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 05/31/2001 | WO2001038314A1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| 05/31/2001 | WO2001038313A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p39 kINASE INHIBITORS |
| 05/31/2001 | WO2001038312A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS |
| 05/31/2001 | WO2001038304A1 Heterocyclic ketone and thioester compounds and uses |
| 05/31/2001 | WO2001037878A2 Methods of identifying optimal drug combinations and compositions thereof |
| 05/31/2001 | WO2001037868A1 Assays and therapies for latent viral infection |
| 05/31/2001 | WO2001037864A1 A novel method of diagnosing, monitoring, staging, imaging and treating cancer |
| 05/31/2001 | WO2001037861A1 A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance |
| 05/31/2001 | WO2001037852A2 Methods of inhibiting atrophy or promoting hypertrophy |
| 05/31/2001 | WO2001037847A2 Nontoxic vernix compositions and method of producing |
| 05/31/2001 | WO2001037846A1 Method and composition for the treatment of adenoviral ocular infections |
| 05/31/2001 | WO2001037843A1 Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs |
| 05/31/2001 | WO2001037840A1 Methods for treating mild cognitive impairment |
| 05/31/2001 | WO2001037830A1 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 05/31/2001 | WO2001037824A1 Use of 5ht3 agonists for relaxing the fundus |
| 05/31/2001 | WO2001037818A2 Medicament and combination of compatible medicaments |
| 05/31/2001 | WO2001037806A1 Composition and method for treatment of otitis media |
| 05/31/2001 | WO2001037788A1 Topical skin composition |
| 05/31/2001 | WO2001037785A2 Novel methods and compositions involving opioids and antagonists thereof |
| 05/31/2001 | WO2001037782A2 Method and composition for the treatment of scars |
| 05/31/2001 | WO2001037779A2 A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| 05/31/2001 | WO2001009186A3 Therapeutic compounds comprised of anti-fc receptor binding agents |
| 05/31/2001 | WO2001005411A8 Compositions addressing inflammation and/or degenerative disorders |
| 05/31/2001 | WO2001002598A3 Screening for compounds modulating mitochondrial proton leak |
| 05/31/2001 | WO2000072806A3 Sunscreen composition containing sol-gel microcapsules |
| 05/31/2001 | WO2000069472A3 Enzyme-activated anti-tumor prodrug compounds |
| 05/31/2001 | WO2000066708A3 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 05/31/2001 | WO2000064414A3 Solid pharmaceutical formulations of acid-sensitive proton-pump blockers |
| 05/31/2001 | WO2000055345A3 Therapy of cancer by insect cells containing recombinant baculovirus encoding genes |
| 05/31/2001 | WO2000006712A3 Protein tyrosine phosphatase-1b (ptp-1b) deficient mice and uses thereof |
| 05/31/2001 | WO1999064041A9 Multibinding agents that modulate nmda receptors |
| 05/31/2001 | US20010002421 Exposing intracellular pathogen in cell or animal culture to the test agent in the absence of cyclohexamine and determining the presence/absence of the pathogen by determining the presence/absence of the gene; amplification |
| 05/31/2001 | US20010002406 Administering an anesthetic to the area where capsaicin or an analogue are administered transdermally for neuropathic pain; kits containing two patches; desensitization of C fibers; peripheral neuropathy |
| 05/31/2001 | US20010002403 N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions |
| 05/31/2001 | US20010002400 Administering an antifungal agent |
| 05/31/2001 | US20010002397 24-Hydroxyvitamin D, analogs and uses thereof |
| 05/31/2001 | US20010002396 Comprising a vitamin D analog and a retinoid, vitamin D analog is capable of binding a vitamin D receptor and the retinoid consisting of a compound capable of binding a retinoic acid receptor; treats abnormal cell proliferation |
| 05/31/2001 | US20010002393 Administering to a patient suffering from leiomyoma (fibroid)of uterus an effective dose of an agent which specifically inhibit metalloproteinase selected from stromelysin-2, stromelysin-3 and matrilysin |
| 05/31/2001 | US20010002391 Administering to the mammal for ischmeic treatment an effective amount of an necrosis factor(NF)- kappa B activation inhibitor selected from the group consisting of proteasome inhibitor, ubiquitin pathwaty inhibitors |
| 05/31/2001 | CA2394914A1 A novel method of diagnosing, monitoring, staging, imaging and treating cancer |
| 05/31/2001 | CA2392495A1 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 05/31/2001 | CA2392456A1 Assays and therapies for latent viral infection |
| 05/31/2001 | CA2392365A1 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 05/31/2001 | CA2392362A1 Novel methods and compositions involving opioids and antagonists thereof |
| 05/31/2001 | CA2392356A1 Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs |
| 05/31/2001 | CA2392351A1 Novel transcription factor and dna thereof |
| 05/31/2001 | CA2392217A1 Methods of inhibiting atrophy or promoting hypertrophy |
| 05/31/2001 | CA2392175A1 A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance |
| 05/31/2001 | CA2391575A1 Heterocyclic ketone and thioester compounds and uses |
| 05/31/2001 | CA2390923A1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 05/31/2001 | CA2390802A1 A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| 05/31/2001 | CA2390772A1 Genetic indicators of tobacco consumption |
| 05/31/2001 | CA2390767A1 Nontoxic vernix compositions and method of producing |
| 05/31/2001 | CA2388103A1 Medicament and combination of compatible medicaments |
| 05/30/2001 | EP1103559A1 Autoimmune nucleosides |
| 05/30/2001 | EP1103243A2 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance p |
| 05/30/2001 | EP1102853A1 N-acetylglycosaminyltransferase genes |
| 05/30/2001 | EP1102838A2 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 05/30/2001 | EP1102768A1 Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
| 05/30/2001 | EP1102767A1 Substituted pyrazole derivatives |
| 05/30/2001 | EP1102604A1 Drug releasing elastic band and method |
| 05/30/2001 | EP1102599A1 Protease inhibitors for use in the treatment of psoriasis |
| 05/30/2001 | EP1102598A1 Hair growth/maintenance compositions and methods involving the same |
| 05/30/2001 | EP1102597A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht 4 receptors |
| 05/30/2001 | EP1102594A1 Use of camptothecin derivatives, with reduced gastrointestinal toxicity |
| 05/30/2001 | EP1102593A1 Prostate formula |
| 05/30/2001 | EP1102590A1 Use of a nk-1 receptor antagonist for treating or preventing abnormal bone resorption |
| 05/30/2001 | EP1102589A1 Topical compositions comprising an opioid analgesic and an nmda antagonist |
| 05/30/2001 | EP1102588A1 Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| 05/30/2001 | EP1102587A2 Vitronectin receptor antagonists |
| 05/30/2001 | EP1102584A2 Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid |
| 05/30/2001 | EP1102582A2 Inhibitors of type 3 3alpha-hydroxysteroid dehydrogenase |
| 05/30/2001 | EP1102578A1 A new analgesic, anti-inflammatory and wound healing agent |
| 05/30/2001 | EP1102567A1 Cardiac disease treatment device and method |
| 05/30/2001 | EP0721586B1 Methods and compositions for treatment of bcr-abl associated leukemias and other cell proliferative disorders |
| 05/30/2001 | CN1297532A Identification of chemical active agents for inhibiting 1-desoxy-D-xylulose-5-phosphate biosynthetic pathway in parasites, and said active agents |
| 05/30/2001 | CN1297359A Ophthalmic composition comprising beta-blocker |
| 05/30/2001 | CN1297357A Preventives or remedies for inflammatory intestinal diseases contg. as active ingredient IL-6 antagonists |